When it comes to treating metastatic cancers, the current approach often destroys everything in the path to the tumor, causing harmful side effects. Radiopharmaceutical therapy (RPT) offers a novel alternative by targeting cancer cells directly while sparing healthy tissue. This method has garnered over $17 billion in investments, according to Aptevo Therapeutics Inc. (NASDAQ: APVO). To advance this field, Aptevo and Niowave Inc. have formed a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs.
Under the agreement, Aptevo contributes its multispecific antibody platforms and oncology development expertise, while Niowave provides radioisotope production, supply, and manufacturing capabilities. Niowave also made an equity investment in Aptevo, representing an initial ownership position of 7.9%, with the potential to increase to 19.99% through warrant exercises. This collaboration marks Aptevo's entry into radiopharmaceutical development and Niowave's first foray into therapeutic development beyond isotope supply.
The companies have selected Nectin-4 as their first target, a clinically validated cancer target broadly expressed across solid tumors. Aptevo's multispecific platforms, including ADAPTIR™ and ADAPTIR-FLEX™, will be used to create targeting molecules that direct radioactive payloads to tumors. Niowave will supply actinium-225 and other radioisotopes, addressing supply constraints that have limited the field.
Jeff Lamothe, President and CEO of Aptevo, stated: "We have established a strong foundation with our multispecific assets, and this partnership enables us to extend that capability into radiopharmaceuticals." Mike Zamiara, CEO of Niowave, added: "This collaboration will deepen our radiopharmaceutical development capabilities and better position us to support current partners and the broader industry."
The timing of the collaboration aligns with growing Big Pharma interest in radiopharmaceuticals, as evidenced by recent investments. The companies aim to overcome limitations in isotope access and manufacturing infrastructure, potentially advancing new treatment options for patients with difficult-to-treat cancers. The first stage of the collaboration is already underway, with results expected to inform future development steps.
For more information about Aptevo Therapeutics, visit their website. This content was originally published on Benzinga.
